Effect of liver damage on the pharmacokinetics of dexamethasone.
By measuring the pharmacokinetics of dexamethasone in 48 patients with various degrees of disturbances in liver function, we could demonstrate a decrease in the metabolic clearance of this steroid by 53% if the activity of the plasma cholinesterase was lowered to less than 2 kU/l. Results suggest that the dosage of dexamethasone given for diagnostic or therapeutic purpose needs to be adjusted in such patients.